🐾Second Annual Animal Drug User Fee Educational Conference Announcement
The Food and Drug Administration (FDA, the Agency, or we) is announcing the following educational conference (public meeting) entitled "Second Annual Animal Drug User Fee Educational Conference." This is the second of five annual educational conferences FDA will host as described in the "Animal Drug User Fee Act Reauthorization Performance Goals and Procedures Fiscal Years 2024 Through 2028." The purpose of this series of conferences is to provide educational sessions for stakeholders who are interested in the new animal drug approval process.
Learn More🐾FDA Final Rule on New Animal Drug Regulations Effective May 2025
The Food and Drug Administration (FDA or we) is amending the animal drug regulations to reflect application-related actions for new animal drug applications (NADAs), abbreviated new animal drug applications (ANADAs), and conditionally approved new animal drug applications (CNADAs) during January, February, and March 2025. The animal drug regulations are also being amended to improve their accuracy and readability.
Learn More⚖️DEA Revocation Order Impacting Texas Veterinarian Registration
The Drug Enforcement Administration (DEA) has issued a final order revoking the registration of Linwood A. Starks, D.V.M., due to his inability to practice veterinary medicine in Texas. The decision is based on the registrant's default following a suspension of his state veterinary license, highlighting the importance of state authority in maintaining a DEA registration for handling controlled substances.
Learn More🐾New Animal Drug Regulations Affecting Compliance and Approval Processes
The Food and Drug Administration (FDA or we) is amending the animal drug regulations to reflect application-related actions for new animal drug applications (NADAs) and abbreviated new animal drug applications (ANADAs) during October, November, and December 2024. The animal drug regulations are also being amended to improve their accuracy and readability.
Learn More🐾FDA Seeks Input on Cannabis-Derived Products in Veterinary Use
The Food and Drug Administration (FDA, the Agency, or we) is soliciting comments from the public, particularly veterinarians, related to the use of cannabis-derived products (CDPs) in animals, with an emphasis on cannabidiol (CBD) products and general trends associated with those products, including information about: usage trends (e.g., product selection, indications, etc.), quality standards, benefits of use, potential drug interactions, adverse events and safety problems, and toxicological concerns. This information will enhance the Center for Veterinary Medicine's (CVM's) knowledge of potential safety signals associated with these products, in addition to aiding our understanding of veterinarians' experiences related to the use of CDPs for their animal patients.
Learn More